safenolaTiCancerDrug
Financiado
Highly and Widely Effective Water Stable and Non Toxic Titanium Phenolato base...
Highly and Widely Effective Water Stable and Non Toxic Titanium Phenolato based Anticancer Chemotherapy
Chemotherapy is the most common line of treatment for various cancer types, but it generally suffers from severe side effects. Cisplatin is a highly effective metallodrug employed in the clinic, limited by severe and irreversible...
Chemotherapy is the most common line of treatment for various cancer types, but it generally suffers from severe side effects. Cisplatin is a highly effective metallodrug employed in the clinic, limited by severe and irreversible nephro- and neurotoxicities and resistance development. Therefore, developing highly and widely effective chemotherapy that is non- or substantially less- toxic should impact immediately and significantly the welfare of society. The titanium metal is an attractive Pt alternative, as it is bio-friendly and non-toxic. Titanium dioxide, the final decomposition product of Ti complexes in water, is a safe material often found in food and cosmetics. Nevertheless, the rapid dissociation of past Ti complexes in water has hampered their development into drugs.
Under an ERC-StG grant followed by an ERC-CoG grant, the PI has developed Ti(IV) complexes that are stable for weeks in water, with high in vitro activity toward numerous cells (also established on the NCI-60 panel of the NIH) and in vivo toward murine and human models with no clinical sights of toxicity in treated mice at effective doses, where mortality occurred in control animals treated with cisplatin at similar doses. Pharmaceutical entities have shown specific interest in taking the proposed compound 1 into clinical trials phase I. Some experiments are still required before an agreement can be made, as proposed herein. Through the parent ERC-CoG, mechanistic analyses are ongoing, but no animal studies are permitted. Thus, through the proposed study: (a) pharmacokinetic studies on compound 1 by ICP-MS will determine absorption, bio-distribution, and excretion; (b) In vivo studies of different models and with varying concentrations and formulation types will determine the therapeutic potential; (c) iv vivo combination studies will identify possible lines of treatments. These studies should promote the interaction with pharmaceutical companies to enable compound 1 to enter clinical trials.
ver más
Duración del proyecto: 18 meses
Fecha Inicio: 2017-10-18
Fecha Fin: 2019-04-30
Fecha Fin: 2019-04-30
Línea de financiación: concedida
El organismo H2020 notifico la concesión del proyecto el día 2019-04-30
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
ERC-2017-PoC:
ERC-Proof of Concept
Cerrada
hace 7 años
Presupuesto
El presupuesto total del proyecto asciende a
150K€
Líder del proyecto
THE HEBREW UNIVERSITY OF JERUSALEM
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5
637.71K€ |
Participante